Tag: CELLB9®
March 25, 2019
PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
PreveCeutical Medical Inc. (CSE:PREV, OTC:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each...
March 11, 2019
PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
PreveCeutical Medical Inc. (CSE:PREV) (OTC:PRVCF) (FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce positive results from the preliminary screening of key... February 13, 2019
PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical") is pleased to announce the appointment of Dr. Makarand (Mak)... February 12, 2019
PreveCeutical Announces Closing of Non-Brokered Private Placement
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical") announces the closing of a non-brokered private placement financing (the... January 29, 2019
PreveCeutical to Explore Partnerships with Pharmaceutical and Biotechnology Companies for the Co-Development of its Sol-Gel System
PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) (the "Company" or "PreveCeutical"), announces that it plans to commence exploratory discussions with pharmaceutical... January 14, 2019
PreveCeutical Provides Update on the Dual Gene Therapy Program
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical") is pleased to provide an update on its dual gene therapy... January 8, 2019